OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office

July 9, 2023

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection.

Importantly, the Notice of Allowance follows the patent protection previously granted to OMN6 in several other major international markets, including the United States, European Union, China, Australia, and Japan. The repeated validation from patent offices worldwide testifies to the unique, innovative, and significant nature of our work in fighting infectious diseases.

Our dedicated team of scientists has invested countless hours in the development of this peptide, with the goal of delivering a novel, effective, and accessible solution for AMR and for the treatment of infectious diseases globally.

With this Notice of Allowance, the intellectual property for our lead peptide is officially recognized and protected until 2037. This provides our company with the exclusive rights to further develop and commercialize our pioneering antimicrobial peptide. It also ensures that we can continue our vital work to advance this treatment without the fear of any patent infringement.

As we move forward, we remain committed to pushing the boundaries of biotechnology to improve healthcare outcomes worldwide. We will keep you updated as we embark on the next clinical phase of our journey.

Thank you for your continued support and trust in our mission.

More To Explore

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for

Contact Us

Reach US

A-2-Z - Digital Accessibility and Marketing

Omnix Medical Ltd. is committed to making its website and all its electronic information easier to use and more accessible for people with disabilities. The company’s website was created and/or updated according to the provisions of the Equal Rights for People with Disabilities Law, 5748-1998, and the delegated legislation stemming from it, and it fully complies with the W3C Web Content Accessibility Guidelines 2.0, AA level.

Omnix Medical Ltd. will continue its efforts to constantly improve the accessibility of its website and information in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use also for those of us with disabilities.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).